Bicycle Therapeutics (BCYC) Other Non-Current Liabilities (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Other Non-Current Liabilities came in at $931000.0 in Q2 2026, down 18.26% YoY from $1.1 million in Q2 2025, and down 4.32% on a QoQ basis from $973000.0 in Q1 2026.
Bicycle Therapeutics (BCYC) Other Non-Current Liabilities (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Other Non-Current Liabilities data on file, last reported at $931000.0 in Q2 2026.
- Quarterly Other Non-Current Liabilities fell 18.26% year-over-year to $931000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $931000.0 (down 18.26% YoY) and the FY2025 annual result came in at $1.0 million, down 7.94% from the prior year.
- Other Non-Current Liabilities declined to $931000.0 in Q2 2026, from $973000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $6.0 million in Q3 2024 to a low of $931000.0 in Q2 2026.
- A 5-year average of $3.0 million and a median of $3.3 million in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities soared 38.16% — and 2025, when it plunged 81.67%.
- Tracing BCYC's Other Non-Current Liabilities over 5 years: stood at $3.8 million in 2022, then gained by 19.59% to $4.6 million in 2023, then tumbled by 75.52% to $1.1 million in 2024, then retreated by 7.94% to $1.0 million in 2025, then retreated by 9.79% to $931000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $931000.0 (Q2 2026), $973000.0 (Q1 2026), and $1.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 931,000.00 |
| Mar 31, 2026 | 973,000.00 |
| Dec 31, 2025 | 1.03 Mn |
| Sep 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 1.14 Mn |
| Mar 31, 2025 | 1.12 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | 5.96 Mn |
| Jun 30, 2024 | 4.70 Mn |
| Mar 31, 2024 | 4.61 Mn |
| Dec 31, 2023 | 4.58 Mn |
| Sep 30, 2023 | 4.32 Mn |
| Jun 30, 2023 | 4.33 Mn |
| Mar 31, 2023 | 4.08 Mn |
| Dec 31, 2022 | 3.83 Mn |
| Sep 30, 2022 | 3.16 Mn |
| Jun 30, 2022 | 3.26 Mn |
| Mar 31, 2022 | 3.36 Mn |
| Dec 31, 2021 | 3.28 Mn |
| Sep 30, 2021 | 3.04 Mn |